NCT06276491 2026-03-17Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsXencor, Inc.Phase 1 Recruiting282 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA